EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retrospective study on the clinical outcomes and characteristics of acute myeloid leukemia: different outcomes in the same risk group

Fanqiao Meng, Maoyuan Xiang, Huan Xie, Yu Liu, Yan Qi, Dongfeng Zeng

PeerJ · 2025

DOI: 10.7717/peerj.20436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Fanqiao Meng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Daping Hospital, The Third Military Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Army Medical Center of PLA Talent Innovation Ability Training Program, Chongqing Natural Science Foundation, The Army Medical Center of PLA Talent Innovation Ability Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute myeloid leukemia (AML) remains a prognostically heterogeneous malignancy despite advances in molecular risk stratification. While the 2022 European Leukemia Network (ELN) guidelines refine risk classification, their accuracy in predicting survival outcomes across genetic requires validation.

Methods

We conducted a retrospective analysis of 154 newly diagnosed AML patients at Daping Hospital, integrating next-generation sequencing (NGS)-based genetic profiling, 2022 ELN risk classification, and clinical outcomes.

Results

The most frequent mutations were FLT3 (26.6%), DNMT3A (21.4%), NPM1 (18.2%), CEBPA (17.5%), and TET2 (15.6%). Median overall survival (OS) and progression-free survival (PFS) were 22.9 months and 14.1 months, respectively. Hematopoietic stem cell transplantation (HSCT), female sex, age < 60 years, and normal karyotype emerged as favorable prognostic factors. No significant differences were observed between allogeneic (allo-HSCT) and autologous HSCT (ASCT). Idarubicin, cytarabine, etoposide (IA ± E) chemotherapy yielded superior survival, while azacitidine+venetoclax (AZA+VEN) regimens underperformed. Conversely, TP53 and KIT mutations correlated with inferior survival, while NPM1, CEBPA mutations predicted longer survival. Notably, significant survival heterogeneity existed within 2022 ELN risk groups, particularly among patients with FLT3 , CEBPA , or TET2 mutations.

Conclusions

The ELN risk classification demonstrate limitations in prognostication, particularly for patients with FLT3 , CEBPA , or TET2 mutations. Our findings highlight the necessity for refined risk models incorporating additional molecular markers ( KIT ) and mutation interactions to enhance personalized prognostication. Gene coexistence is also a factor that needs to be considered when determining patient prognosis.

Trial registration

The study was registered on the Chinese clinical trial registry (ChiCTR) platform (No. ChiCTR2500096484).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansFemaleMaleMiddle AgedNucleophosminRetrospective StudiesAdultHematopoietic Stem Cell TransplantationMutationAgedYoung AdultPrognosisDioxygenasesCCAAT-Enhancer-Binding Proteinsfms-Like Tyrosine Kinase 3AdolescentDNA Methyltransferase 3ADNA-Binding ProteinsProto-Oncogene ProteinsHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

Acute myeloid leukemiaEuropean Leukemia NetworkGenetic heterogeneityPrognostic stratification

Substanzen

NucleophosminNPM1 protein, humanDioxygenasesCCAAT-Enhancer-Binding Proteinsfms-Like Tyrosine Kinase 3CEBPA protein, humanTET2 protein, humanDNA Methyltransferase 3AFLT3 protein, humanDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Hematology, Daping Hospital, The Third Military Medical University, Chongqing, China.

Förderung

  • Army Medical Center of PLA Talent Innovation Ability Training Program
  • Chongqing Natural Science Foundation
  • The Army Medical Center of PLA Talent Innovation Ability Training Program

Zitieren

APA

Meng, F., Xiang, M., Xie, H., Liu, Y., Qi, Y., & Zeng, D. (2025). Retrospective study on the clinical outcomes and characteristics of acute myeloid leukemia: different outcomes in the same risk group. PeerJ. https://doi.org/10.7717/peerj.20436

Vancouver

Meng F, Xiang M, Xie H, Liu Y, Qi Y, Zeng D. Retrospective study on the clinical outcomes and characteristics of acute myeloid leukemia: different outcomes in the same risk group. PeerJ. 2025. doi:10.7717/peerj.20436

BibTeX
@article{Meng2025,
  author = {Meng, Fanqiao and Xiang, Maoyuan and Xie, Huan and Liu, Yu and Qi, Yan and Zeng, Dongfeng},
  title = {Retrospective study on the clinical outcomes and characteristics of acute myeloid leukemia: different outcomes in the same risk group},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.20436}
}
Kostenlos starten →